Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kinrix (DTaP-IPV) Booster Consistency and Safety Study
NCT00148941Phase 3Completed
- Sponsor
- GSK
- Start
- Jan 2005
- Primary completion
- Nov 2006
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) in diphtheria, Tetanus, pertussis, poliomyelitis, sponsored by GSK. Started Jan 2005; status: completed.
02
Drugs
Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated)
03
Conditions
diphtheriaTetanuspertussispoliomyelitis
Beyond the preview
Go deeper on NCT00148941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00148941.